

JEM online**TRY****Journal of Cell
Biology Online****HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH SEARCH RESULT**

Journal of Experimental Medicine, Vol 180, 2359-2364, Copyright © 1994 by
Rockefeller University Press

ARTICLES

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

JD Taurog, JA Richardson, JT Croft, WA Simmons, M Zhou, JL Fernandez-Sueiro, E Balish and RE Hammer

Harold C. Simmons Arthritis Research Center, University of Texas Southwestern Medical Center, Dallas 75235.

A number of inflammatory disease states occur with greatly increased frequency in individuals inheriting the human major histocompatibility complex class I allele HLA-B27. In a minority of cases, namely those with B27-associated reactive arthritis, there is good evidence that the disease state is triggered by infection with an enteric or genitourinary bacterial pathogen. For the majority of B27-associated disease, no definite pathogenetic role for bacteria has been established. However, in these latter cases intestinal inflammation can often be demonstrated, and it sometimes occupies a major part of the clinical picture. Rats transgenic for B27 are known to develop a disorder resembling B27-associated human disease, with prominent intestinal, joint, skin, and male genital inflammatory lesions. We report here that B27 transgenic rats raised in a germfree environment do not develop inflammatory intestinal or peripheral joint disease, whereas the skin and genital inflammatory lesions are unaffected by the germfree state. These findings support the concept that gut and joint inflammation are pathogenetically closely related, and they provide direct evidence that the commensal gut flora play an important role in the pathogenesis of B27-associated gut and joint inflammation.

- ▶ Similar articles found in:
[JEM Online](#)
[PubMed](#)
- ▶ [PubMed Citation](#)
- ▶ Search Medline for articles by:
[Taurog, J.](#) || [Hammer, R.](#)
- ▶ Alert me when:
[new articles cite this article](#)
- ▶ [Download to Citation Manager](#)

This article has been cited by other articles:

- Kawachi, S., Jennings, S., Panes, J., Cockrell, A., Laroux, F. S., Gray, L., Perry, M., van der Heyde, H., Balish, E., Granger, D. N., Specian, R. A., Grisham, M. B. (2000). Cytokine and endothelial cell adhesion molecule expression in interleukin-10-deficient mice. *Am. J. Physiol.* 278: 734-743 [[Abstract](#)] [[Full Text](#)]
- Oldstone, M. B. A. (1998). Molecular mimicry and immune-mediated diseases. *FASEB J.* 12: 1255-1265 [[Abstract](#)] [[Full Text](#)]
- FIOCCHI, C. (1998). Inflammatory Bowel Disease: Etiology and Pathogenesis. *Gastroenterology* 115: 182-205 [[Full Text](#)]
- DARFEUILLE-MICHAUD, A., NEUT, C., BARNICH, N., LEDERMAN, E., DI MARTINO, P., DESREUMAUX, P., GAMBIEZ, L., JOLY, B., CORTOT, A., COLOMBEL, J.-F. (1998).

L9 ANSWER 1 OF 3 MEDLINE
AN 96281915 MEDLINE
DN 96281915
TI **HLA-DR4-IE** chimeric class II **transgenic**, murine class
II-deficient mice are susceptible to experimental allergic
encephalomyelitis.
AU Ito K; Bian H J; Molina M; Han J; Magram J; Saar E; Belunis C; Bolin D R;
Arceo R; Campbell R; Falcioni F; Vidovic D; Hammer J; Nagy Z A
CS Department of Inflammation and Autoimmune Diseases, Hoffmann-La Roche
Inc., Nutley, New Jersey 07110, USA.
SO **JOURNAL OF EXPERIMENTAL MEDICINE**, (1996 Jun 1) 183 (6)
2635-44.
Journal code: I2V. ISSN: 0022-1007.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; Cancer Journals
EM 199610
AB To investigate the development of **HLA-DR**-associated autoimmune
diseases, we generated **transgenic** (Tg) mice with **HLA**
-DRA-IE alpha and **HLA-DRB1*0401**-IE beta chimeric genes. The
transgene-encoded proteins consisted of antigen-binding domains from
HLA-DRA and **HLA-DRB1*0401** molecules and the remaining
domains from the IE(d)-alpha and IE(d)-beta chains. The chimeric
molecules
showed the same antigen-binding specificity as **HLA-DRB1*0401**
molecules, and were functional in presenting antigens to T cells. The Tg
mice were backcrossed to MHC class II-deficient (IA beta-, IE alpha-)
mice
to eliminate any effect of endogenous MHC class II genes on the
development of autoimmune diseases. As expected, IA alpha beta or IE
alpha
beta molecules were not expressed in Tg mice. Moreover, cell-surface
expression of endogenous IE beta associated with **HLA-DRA-IE**
alpha was not detectable in several Tg mouse lines by flow cytometric
analysis. The **HLA-DRA-IE** alpha/**HLA-DRB1*0401**-IE beta
molecules rescued the development of CD4+ T cells in MHC class
II-deficient mice, but T cells expressing V beta 5, V beta 11, and V beta
12 were specifically deleted. Tg mice were immunized with peptides,
myelin
basic protein (MBP) 87-106 and proteolipid protein (PLP) 175-192, that
are
considered to be immunodominant epitopes in **HLA-DR4** individuals.
PLP175-192 provoked a strong proliferative response of lymph node T cells
from Tg mice, and caused inflammatory lesions in white matter of the CNS
and symptoms of experimental allergic encephalomyelitis (EAE).
Immunization with MBP87-106 elicited a very weak proliferative T cell
response and caused mild EAE. Non-Tg mice immunized with either
PLP175-192
or MBP87-106 did not develop EAE. These results demonstrated that a human
MHC class II binding site alone can confer susceptibility to an
experimentally induced murine autoimmune disease.

L4 ANSWER 1 OF 3 MEDLINE
 AN 89035546 MEDLINE
 DN 89035546
 TI HLA-B27 in inbred and non-inbred **transgenic** mice. Cell surface expression and recognition as an alloantigen in the absence of human beta 2-microglobulin.
 AU **Taurog J D**; Lowen L; Forman J; Hammer R E
 CS Harold C. Simmons Arthritis Research Center, University of Texas, Dallas 75235.
 NC AR38319 (NIAMS)
 AI13111 (NIAID)
 AI11851 (NIAID)
 +
 SO JOURNAL OF IMMUNOLOGY, (1988 Dec 1) 141 (11) 4020-3.
 Journal code: IFB. ISSN: 0022-1767.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals; Cancer Journals
 EM 198902
 AB A gene encoding the H chain of the human class I MHC Ag HLA-B27 was introduced into the germ lines of inbred C57BL/6 (B6) and non-inbred (B6 X SJL/J) F2 mice. By immunofluorescence and flow cytometry, the HLA-B27 gene product was expressed on lymphoid cells at levels comparable to the endogenous H-2b and H-2s class I MHC molecules. In both primary and secondary MLC between responder spleen cells from non-**transgenic** (B6 X SJL/J) F1 mice and **transgenic** stimulator cells, CTL were generated that specifically lysed mouse L cell (H-2k) or human B cell targets expressing HLA-B27, and this lysis thus appeared largely unrestricted by H-2. These results indicate that **transgenic** mice express a functional HLA-B27 gene product on cell surfaces in the absence of the human beta 2-microglobulin gene. These **transgenic** mice promise to be a valuable resource in the investigation of the unique role of HLA-B27 in inflammatory human disease.

DUPLICATE 1

(FILE 'HOME' ENTERED AT 14:28:33 ON 05 APR 2001)

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 14:28:41 ON 05 APR 2001
E TAUROG/AU

L1 539 S E3-E11
L2 32 S L1 AND PY=1988
L3 6 S L2 AND TRANSGENIC#
L4 3 DUP REM L3 (3 DUPLICATES REMOVED)
E ITO/AU
E JOURNAL OF EXPERIMENTAL MED?/JT
L5 15470 S E4, E5
L6 1093 S L5 AND PY=1996
L7 122 S L6 AND TRANSGENIC#
L8 6 S L7 AND HLA?
L9 3 DUP REM L8 (3 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:35:42 ON 05 APR 2001

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 14:39:02 ON 05 APR 2001

L10 19 S L1 AND PY=1994
L11 9 S L10 AND TRANSGENIC#
L12 7 DUP REM L11 (2 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:40:53 ON 05 APR 2001

L13 1 S TRANSGENIC#

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 14:43:33 ON 05 APR 2001

L14 99873 S TRANSGENIC#
L15 1019761 S ANTIGEN#
L16 13778 S L14 AND ANTIGEN##
L17 1087 S L16 AND (HLA? OR HUMAN LEUKOCYTE ANTIGEN# OR HUMAN
LYMPHOCYTE
L18 1523 S L14 AND (HLA? OR HUMAN LEUKOCYTE ANTIGEN# OR HUMAN
LYMPHOCYTE
L19 1347 S L14 (P) (HLA? OR HUMAN LEUKOCYTE ANTIGEN# OR HUMAN
LYMPHOCYTE
L20 55 S L19 AND (TAA# OR MART? OR MAGE? OR GP100 OR TUMOR# (5A)
ANTIG
L21 5 S L20 AND (TCR OR TCRS OR T CELL RECEPTOR#)
L22 4 DUP REM L21 (1 DUPLICATE REMOVED)

FILE 'STNGUIDE' ENTERED AT 14:53:13 ON 05 APR 2001

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 14:53:36 ON 05 APR 2001

L23 50 S L20 NOT L21
L24 29 DUP REM L23 (21 DUPLICATES REMOVED)
L25 8 S L24 NOT PY>1997

FILE 'STNGUIDE' ENTERED AT 15:00:26 ON 05 APR 2001

FILE 'MEDLINE, BIOSIS, CAPLUS' ENTERED AT 15:02:57 ON 05 APR 2001